Effect of herbal medicine containing Saatar, Hofarigon and Fennel on COVID-19 patients

Evaluation of the effect of herbal medicine containing Saatar, Hofarigon and Fennel on reduction of pulmonary complications of COVID-19 in patients: a clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200404046935N1

Enrollment

Registered

2020-04-20

Start date

2020-04-18

Completion date

Unknown

Last updated

2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. Coronavirus infection, unspecified

Interventions

Intervention 1: Intervention group: Kaletra 200 mg/50 mg tablet every 12 hours + hydroxychloroquine 200 mg tablets every 12 hours + herbal medicine containing sage, hofariqun and fennel (5 ml 3 times

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Temperatures above 2 degrees Lymphocyte count less than 2 CRP positive Respiratory symptoms Symptoms of pulmonary involvement in CT scan Satisfaction to participate in the study Age older than 18 years

Exclusion criteria

Exclusion criteria: Oral intolerance Pulmonary disease

Design outcomes

Primary

Measure	Time frame
Fever. Timepoint: Every day for 7 days. Method of measurement: termometer.;Lymphocyte count. Timepoint: Before and 7 days after intervention. Method of measurement: Cell counter device.;Erythrocyte sedimentation rate. Timepoint: Before and 7 days after intervention. Method of measurement: ESR device.	—

Secondary

Measure	Time frame
Pneumonia. Timepoint: Before and 14 days after intervention. Method of measurement: CT-Scan.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarhang Babamahmoodi

Mazandaran University of Medical Sciences

farhang.baba@yahoo.com+98 11 4221 8231

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026